Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E1K Single Dose in Knee Osteoarthritis
NCT05697952Phase 2Completed
- Sponsor
- Ensol Biosciences Inc.
- Start
- Jun 2022
- Primary completion
- Nov 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Engedi1000 in knee osteoarthritis (OA) (3 arms), sponsored by Ensol Biosciences Inc. Primary endpoint: Western Ontario and McMaster Universities Osteoarthritis Index at 12 weeks. Started Jun 2022; status: completed.
02
Drugs
Engedi1000
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05697952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05697952.